Research programme: neurodegenerative disorder therapeutics - Kadimastem/Merck Serono

Drug Profile

Research programme: neurodegenerative disorder therapeutics - Kadimastem/Merck Serono

Latest Information Update: 05 Oct 2015

Price : $50

At a glance

  • Originator Kadimastem; Merck Serono
  • Class
  • Mechanism of Action Glial cell modulators; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Multiple sclerosis; Neurodegenerative disorders

Most Recent Events

  • 29 Sep 2015 Kadimastem receives grant from the National Multiple Sclerosis Society for the development in nerve-insulating myelin in Multiple sclerosis
  • 07 Aug 2014 Early research in Neurodegenerative disorders in Israel (PO)
  • 01 May 2014 Early research is ongoing in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top